• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Global Biosimilar Market Outlook 2018 - Product Image

Global Biosimilar Market Outlook 2018

  • Published: February 2014
  • Region: Global
  • 145 Pages
  • RNCOS E-Services Private Limited

FEATURED COMPANIES

  • 3 SBio Inc.
  • Bioton
  • Dr.Reddy's Labs (DRL)
  • Hospira
  • Ratiopharm GmbH
  • Sandoz GmbH
  • MORE

The global biosimilars market is at a crucial turning point, as biosimilars are gaining wide acceptance around the world, with regulatory pathways being clearly defined in every region and R&D investments being at an all time high. Several biosimilars have entered the market over the past 2-3 years. In 2008, Merck, one of the big pharma manufacturers, embraced biosimilars. Large scale partnerships to develop biosimilars are also being announced such as those between Samsung and Biogen, Amgen and Watson, Dr. Reddy’s and Merck Serano.

According to our latest research report, “Global Biosimilar Market Outlook 2018”, although the current biosimilars market is small, the future looks optimistic with number of innovative biologics going off patent. Our report discusses major trends and drivers in detail and the influence they will have on the market. Emerging markets will play the role of a major driver for the biosimilars market, which will be attributed to the local policies and the biosimilar attitude of the regions. The governments in the emerging economies are encouraging the growth of biosimilars by defining clear regulatory pathways.

In our report, READ MORE >

1. Analyst View

2. Research Methodology

3. Biologics Market Outlook to 2018
3.1 Market Size
3.2 Market Segmentation

4. Market Trends & Drivers
4.1 Emerging Markets to Play a Pivotal Role in the Growth of Biosimilars
4.2 Rising Business Alliances Aiding in Biosimilar Development
4.3 Governments Realizing the Potential in Biosimilars, Encouraging Industry Growth

5. Biosimilars Market Outlook to 2018
5.1 Market Size
5.2 Market Segmentation
5.2.1 Erythropoietin
5.2.1.1 Scientific Insight
5.2.1.2 Market Analysis
5.2.1.3 Recent Activities
5.2.2 Human Growth Hormone
5.2.2.1 Scientific Insight
5.2.2.2 Market Analysis
5.2.2.3 Recent Activities
5.2.3 G-CSF
5.2.3.1 Scientific Insight
5.2.3.2 Market Analysis
5.2.3.3 Recent Activities
5.2.4 Monoclonal Antibody
5.2.4.1 Scientific Insight
5.2.4.2 Market Analysis
5.2.4.3 Recent Activities
5.2.5 Human Insulin
5.2.5.1 Scientific Insight
5.2.5.2 Market Analysis
5.2.5.3 Recent Activities
5.2.6 Interferons
5.2.6.1 Scientific Insight
5.2.6.2 Market Analysis

6. Major Geographical Market
6.1 US
6.1.1 Market Analysis
6.1.2 Regulatory Analysis
6.1.3 Recent Activities
6.2 Europe
6.2.1 Market Analysis
6.2.2 Regulatory Analysis
6.2.3 Recent Activities
6.3 India
6.3.1 Market Analysis
6.3.2 Regulatory Analysis
6.3.3 Recent Activities
6.4 China
6.4.1 Market Analysis
6.4.2 Regulatory Analysis
6.4.3 Recent Activities
6.5 Korea
6.5.1 Market Analysis
6.5.2 Regulatory Analysis
6.5.3 Recent Activities

7. Competitive Landscape (Key Products & Recent Activities)
7.1 US
7.1.1 Hospira
7.2 Europe
7.2.1 Stada Arzneimittel
7.2.2 Hexal AG
7.2.3 Ratiopharm GmbH
7.2.4 Sandoz GmbH
7.2.5 Bioton
7.3 India
7.3.1 Dr.Reddy's Labs (DRL)
7.3.2 Intas Pharmaceuticals Ltd.
7.3.3 Biocon Limited
7.3.4 Wockhardt Limited
7.3.5 Shantha Biotechnics Limited
7.3.6 Reliance Life Sciences
7.4 China
7.4.1 3 SBio Inc.
7.5 Korea
7.5.1 LG Life Sciences
7.5.2 Celltrion Pharm Inc.
7.5.3 Dong-A Pharmaceutical Co., Ltd
7.6 Others
7.6.1 Teva

- 3 SBio Inc.
- Biocon Limited
- Bioton
- Celltrion Pharm Inc.
- Dong-A Pharmaceutical Co., Ltd
- Dr.Reddy's Labs (DRL)
- Hexal AG
- Hospira
- Intas Pharmaceuticals Ltd.
- LG Life Sciences
- Ratiopharm GmbH
- Reliance Life Sciences
- Sandoz GmbH
- Shantha Biotechnics Limited
- Stada Arzneimittel
- Teva
- Wockhardt Limited

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos